Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TNYA |
---|---|---|
09:32 ET | 8376 | 3.75 |
09:36 ET | 5991 | 3.615 |
09:38 ET | 1789 | 3.62 |
09:39 ET | 1476 | 3.6 |
09:41 ET | 500 | 3.64 |
09:43 ET | 300 | 3.65 |
09:45 ET | 899 | 3.69 |
09:48 ET | 440 | 3.66 |
09:50 ET | 1000 | 3.66 |
09:52 ET | 100 | 3.695 |
09:54 ET | 2007 | 3.66 |
09:56 ET | 100 | 3.64 |
09:57 ET | 800 | 3.7 |
09:59 ET | 216 | 3.72 |
10:01 ET | 406 | 3.67 |
10:03 ET | 100 | 3.65 |
10:06 ET | 200 | 3.65 |
10:08 ET | 300 | 3.65 |
10:10 ET | 500 | 3.63 |
10:12 ET | 1542 | 3.645 |
10:14 ET | 500 | 3.62 |
10:15 ET | 1591 | 3.63 |
10:17 ET | 640 | 3.62 |
10:19 ET | 1135 | 3.65 |
10:21 ET | 500 | 3.66 |
10:24 ET | 889 | 3.68 |
10:26 ET | 754 | 3.712 |
10:28 ET | 324 | 3.7 |
10:30 ET | 1000 | 3.6901 |
10:33 ET | 583 | 3.73 |
10:35 ET | 100 | 3.69 |
10:37 ET | 100 | 3.69 |
10:39 ET | 100 | 3.715 |
10:44 ET | 1853 | 3.735 |
10:46 ET | 517 | 3.77 |
10:48 ET | 2000 | 3.7201 |
10:50 ET | 100 | 3.77 |
10:51 ET | 200 | 3.73 |
10:53 ET | 800 | 3.74 |
10:55 ET | 5100 | 3.755 |
11:00 ET | 100 | 3.74 |
11:02 ET | 200 | 3.74 |
11:08 ET | 200 | 3.7 |
11:11 ET | 200 | 3.7 |
11:13 ET | 100 | 3.7 |
11:15 ET | 250 | 3.7059 |
11:20 ET | 100 | 3.74 |
11:22 ET | 100 | 3.7 |
11:24 ET | 100 | 3.7 |
11:26 ET | 100 | 3.715 |
11:27 ET | 483 | 3.74 |
11:31 ET | 200 | 3.71 |
11:33 ET | 200 | 3.725 |
11:38 ET | 100 | 3.74 |
11:40 ET | 200 | 3.71 |
11:49 ET | 100 | 3.74 |
11:58 ET | 317 | 3.73 |
12:02 ET | 335 | 3.69 |
12:07 ET | 986 | 3.7 |
12:12 ET | 145 | 3.7 |
12:14 ET | 200 | 3.73 |
12:16 ET | 100 | 3.7225 |
12:18 ET | 100 | 3.7 |
12:25 ET | 100 | 3.7 |
12:38 ET | 100 | 3.68 |
12:41 ET | 170 | 3.718 |
12:43 ET | 100 | 3.72 |
12:45 ET | 12935 | 3.7 |
12:50 ET | 300 | 3.7 |
12:52 ET | 100 | 3.68 |
12:54 ET | 1335 | 3.705 |
12:56 ET | 100 | 3.72 |
12:57 ET | 200 | 3.705 |
12:59 ET | 500 | 3.72 |
01:03 ET | 609 | 3.705 |
01:06 ET | 300 | 3.72 |
01:08 ET | 200 | 3.705 |
01:10 ET | 200 | 3.69 |
01:12 ET | 200 | 3.72 |
01:17 ET | 798 | 3.7 |
01:19 ET | 645 | 3.71 |
01:21 ET | 100 | 3.72 |
01:24 ET | 100 | 3.7 |
01:26 ET | 200 | 3.72 |
01:30 ET | 500 | 3.72 |
01:32 ET | 400 | 3.7 |
01:33 ET | 100 | 3.71 |
01:35 ET | 100 | 3.7 |
01:37 ET | 540 | 3.7 |
01:42 ET | 100 | 3.71 |
01:44 ET | 293 | 3.7 |
01:46 ET | 100 | 3.72 |
01:48 ET | 300 | 3.72 |
01:50 ET | 100 | 3.715 |
01:51 ET | 305 | 3.73 |
01:53 ET | 500 | 3.715 |
01:55 ET | 5544 | 3.73 |
01:57 ET | 300 | 3.715 |
02:00 ET | 100 | 3.715 |
02:06 ET | 333 | 3.72 |
02:11 ET | 100 | 3.71 |
02:13 ET | 1698 | 3.71 |
02:15 ET | 500 | 3.71 |
02:18 ET | 500 | 3.7 |
02:20 ET | 100 | 3.7 |
02:22 ET | 200 | 3.7 |
02:24 ET | 200 | 3.69 |
02:29 ET | 850 | 3.68 |
02:31 ET | 100 | 3.67 |
02:33 ET | 200 | 3.67 |
02:36 ET | 420 | 3.7 |
02:38 ET | 300 | 3.68 |
02:42 ET | 408 | 3.68 |
02:44 ET | 1070 | 3.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tenaya Therapeutics Inc | 288.9M | -2.2x | --- |
Zura Bio Ltd | 290.4M | -2.4x | --- |
Solid Biosciences Inc | 298.2M | -2.0x | --- |
Q32 Bio Inc | 286.5M | -0.8x | --- |
Inozyme Pharma Inc | 300.0M | -3.4x | --- |
Alto Neuroscience Inc | 309.7M | -6.4x | --- |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $288.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.65 |
Book Value | $2.04 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.